Syngene International Ltd. (SYNGENE) AI Stock Analysis

7 Followers

Syngene International Ltd.

(NSE:SYNGENE)

Select Model

Rating:66Neutral

Price Target:INR 483.00▲(8.61% Upside)

Action:reiterated

Date:10/29/26

Solid financial performance with a strong balance sheet and reliable cash generation is the primary positive driver, offset by expensive valuation and mixed technical signals showing short-term strength but longer-term resistance.

Positive Factors

Conservative balance sheetImproving leverage and a growing equity base give Syngene financial flexibility to fund research, capacity, and client programs without relying heavily on debt. This conservative capitalization should help the company absorb operating volatility and preserve strategic options over the next several quarters.

Negative Factors

FY2026 revenue contractionThe sharp FY2026 revenue decline interrupts Syngene's prior growth trajectory and raises concern about the near-term utilization of its research and manufacturing platform. If weaker demand or project timing persists, lower scale could pressure margins and delay the return to stronger earnings growth.

Syngene International Ltd. (SYNGENE) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 148.36B
Dividend Yield: 0.28%
Average Volume (3M): 152.18K
Price to Earnings (P/E): 96.0
Beta (1Y): 0.91
Revenue Growth: -5.99%
EPS Growth: -60.30%
Country: India
Employees: 6,692
Sector: General
Sector Strength: 55
Industry: Specialty Business Services

Syngene International Ltd. Business Overview & Revenue Model

Company Description

Syngene International Limited, an India-based contract research and manufacturing organization (CRAMO), offers a wide array of drug discovery and development solutions to clients across India, the United States, and other international markets. The c...

Syngene International Ltd. Financial Statement Overview

Summary

Strong balance sheet with low leverage and growing equity, supported by consistent operating cash flow and revenue expansion, though 2026 projections indicate margin compression and negative revenue growth.

Income Statement

72Positive

Balance Sheet

85Very Positive

Cash Flow

78Positive

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	35.22B	37.39B	36.42B	34.89B	31.93B	26.04B
Gross Profit	11.39B	12.62B	24.41B	23.50B	21.56B	17.12B
EBITDA	8.23B	9.13B	10.47B	10.73B	9.84B	7.43B
Net Income	1.86B	3.17B	4.96B	5.10B	4.64B	3.96B
Balance Sheet
Total Assets	66.58B	70.55B	67.96B	61.52B	58.31B	55.64B
Cash, Cash Equivalents and Short-Term Investments	5.30B	12.89B	13.97B	10.77B	13.54B	12.81B
Total Debt	5.07B	4.58B	5.78B	5.55B	8.15B	10.22B
Total Liabilities	18.00B	22.16B	20.69B	18.94B	22.13B	22.66B
Stockholders Equity	48.59B	48.39B	47.27B	42.58B	36.18B	32.98B
Cash Flow
Free Cash Flow	0	6.11B	3.98B	5.50B	3.05B	1.05B
Operating Cash Flow	0	9.55B	11.68B	10.42B	8.38B	5.81B
Investing Cash Flow	0	-9.11B	-7.45B	-4.96B	-6.88B	-6.12B
Financing Cash Flow	0	-2.04B	-1.42B	-5.51B	-3.40B	-313.00M

Syngene International Ltd. Technical Analysis

Technical Analysis SentimentPositive

Last Price444.70

Price Trends

50DMA387.69Positive

100DMA400.70Positive

200DMA420.83Positive

Market Momentum

MACD16.71Negative

RSI68.09Neutral

STOCH88.80Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SYNGENE, the sentiment is Positive. The current price of 444.70 is above the 20-day moving average (MA) of 403.11, above the 50-day MA of 387.69, and above the 200-day MA of 420.83, indicating a bullish trend. The MACD of 16.71 indicates Negative momentum. The RSI at 68.09 is Neutral, neither overbought nor oversold. The STOCH value of 88.80 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:SYNGENE.

Syngene International Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:SYNGENE against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:ANTHEM	77Outperform	INR 529.00B	85.88	―	0.21%	-1.20%	18.53%
IN:SYNGENE	66Neutral	INR 180.70B	95.96	―	0.28%	-5.99%	-60.30%
IN:CONCORDBIO	61Neutral	INR 125.76B	44.05	―	1.27%	4.02%	-12.81%
IN:DCAL	57Neutral	INR 27.28B	39.75	―	―	-20.86%	-34.51%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:BIOCON	47Neutral	INR 604.03B	121.75	―	0.14%	5.70%	-24.72%
IN:PANACEABIO	47Neutral	INR 22.07B	-305.52	―	―	10.26%	-162.02%

* General Sector Average

Performance Comparison

IN:SYNGENE and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:SYNGENE	Syngene International Ltd.	444.70	-205.06	-31.56%
IN:BIOCON	Biocon Limited	366.80	-54.00	-12.83%
IN:CONCORDBIO	Concord Biotech Ltd.	594.50	-151.73	-20.33%
IN:DCAL	Dishman Carbogen Amcis Ltd.	173.90	-77.55	-30.84%
IN:PANACEABIO	Panacea Biotec Limited	353.80	-36.00	-9.24%
IN:ANTHEM	Anthem Biosciences Limited	936.40	272.68	41.08%

Syngene International Ltd. Corporate Events

Syngene posts Q2 FY27 earnings call audio for investors

Oct 28, 2026

Syngene International Limited has notified the Indian stock exchanges that the audio recording of its Q2 FY27 post-earnings call held on October 28, 2026 has been uploaded to the company’s website. The disclosure has been made under Regulation 30 of...

Syngene Publishes Investor Presentation for September 2026 Period

Oct 27, 2026

Syngene International Ltd. has released an investor presentation for the quarter and half year ended September 30, 2026, in line with Regulation 30 of SEBI’s Listing Obligations and Disclosure Requirements Regulations, 2015. The document, intended fo...

Syngene Announces Resignation of Corporate Affairs Head

Sep 21, 2026

Syngene International Ltd. has announced the resignation of Mr. Pramuch Goel, Head of Corporate Affairs & Communications and a member of the Executive Committee, effective at the close of business on September 21, 2026. The company has notified the B...

Syngene Schedules Analyst Meet at Kotak Healthcare Forum 2026

Sep 12, 2026

Syngene International Ltd. has scheduled a meeting with analysts and institutional investors at the Healthcare Forum 2026 organized by Kotak in Mumbai on September 17, 2026. The engagement will take place as a physical group and one-on-one investor c...

Syngene Grants 1.43 Million Performance Share Units Under 2023 Long-Term Incentive Plan

Sep 1, 2026

Syngene International has granted 1,426,061 Performance Share Units (PSUs) to eligible employees under its Long Term Incentive Performance Share Plan 2023, following approval by the company’s Nomination and Remuneration Committee. The grant, aligned...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 29, 2026

Syngene International Ltd. AI Stock Analysis